As the genomes of mammalian species become sequenced and gene functions are ascribed, the use of differential gene expression (DGE) to evaluate organ function will become common in the experimental evaluation of new drug therapies. The ability to translate this technology into useful information for human exposures depends on tissue sampling that is impractical or generally not possible in man. The possibility that the DGE of nucleated cells, reticulocytes, or platelets in blood may present the necessary link with target organ toxicity provides an opportunity to correlate preclinical with clinical outcomes. Adriamycin is highly effective alone and more frequently in combination with other chemotherapeutic agents in the treatment of a variety of susceptible malignancies. Adriamycin-induced cardiomyopathy was examined as an endpoint to measure the utility of DGE on whole blood as a predictor of cardiac toxicity. Statistically significant gene changes were observed between relevant blood and cardiac gene profiles that corroborated the accepted mechanisms of toxicity (oxidative stress, effects on carnitine transport, DNA intercalation). There were, however, clear indications that other target organs (bone marrow and intestinal tract) were affected. The divergent expression of some genes between the blood and the heart on day 7 may also indicate the timing and mechanism of development of the cardiomyopathy and confirm current therapeutic approaches for its prevention. The data demonstrate that whole blood gene expression particularly in relation to oxidative stress, in conjunction with standard hematology and clinical chemistry, may be useful in monitoring and predicting cardiac damage secondary to adriamycin administration. Appendices A & B, referenced in this paper, are not printed in this issue of Toxicologic Pathology. They are available as downloadable text files at http://taylorandfrancis.metapress.com/openurl.asp?genre = journal&issn = 0192-6233. To access them, click on the issue link for 30(4), then select this article. A download option appears at the bottom of this abstract. In order to access the full article online, you must either have an individual subscription or a member subscription accessed through www.toxpath.org.
Khetawat G., Faraday N., Nealen ML, Vijayan KV, Bolton E., Noga SJ, Bray PF ( 2000). Human megakaryocytes and platelets contain the estrogen receptor beta and androgen receptor (AR): Testosterone regulates AR expression . Blood95: 2289—2296.
2.
Brugnara C. (2000). Reticulocyte cellular indices: A new approach in the diagnosis of anemias and monitoring of erythropoietic function. Crit Rev Clin Lab Sci37: 93—130.
3.
Doroshow JH, Locker GY, Myers CE (1980). Enzymatic defenses of the mouse heart against reactive oxygen metabolites. J Clin Invest65: 128— 135.
4.
Crosby LM, Hyder KS, DeAngelo AB, Kepler TB, Gaskill B., Benavides GR, Yoon L., Morgan KT (2000). Morphologic analysis correlates with gene expression changes in cultured F344 rat mesothelial cells. Toxicol Appl Pharmacol169: 205—221.
5.
Billingham ME , Mason JW, Bristow MR, Daniels JR (1978). Anthracycline cardiomyopathy monitered by morphologic changes. Cancer Treat Rep62: 865—872.
6.
Rowan RA, Masek MA, Billingham ME (1988). Ultrastructural morphometric analysis of endomyocardial biopsies. Am J Cardiovasc Pathol2: 137—144.
7.
Bristow MR (1978). Early anthracycline cardiotoxicity. Am J Med65: 823— 832.
8.
Yamashita J. , Ogawa M., Shirakusa T. (1995). Plasma endothelin-1 as a marker for doxorubicin cardiotoxicity. Int J Cancer62: 542—547.
9.
Kang YJ, Zhou ZX, Wang GW, Buridi A., Klein JB (2000). Suppression by Metallothionein of Doxorubicin-induced cardiomyocyte apoptosis through inhibition of p38 miton-activated protein kinases. J Biol Chem275: 13690— 13698.
10.
Yen HC, Oberley TD, Vichitbandha S., Ho YS, St Clair DK (1996). The protective role of manganese superoxide dismutase against adriamycin-induced acute cardiac toxicity in transgenic mice. J Clin Invest98: 1253— 1260.
11.
Sayed-Ahmed MM , Shaaraway S., Shouman SA, Osman AM (1999). Reversal of doxorubicin-induced cardiac metabolic damage by L-carnitine. Pharmacol Res39: 289—295.
12.
Abdel-aleem S. , el-Merzabani MM, Sayed-Ahmed M., Taylor DA, Lowe JE (1997). Acute and chronic effects of adriamycin on fatty acid oxidation in isolated cardiac myocytes. J Mol Cell Cardiol29: 789—797.
13.
Andrieu-Abadie N., Jaffrezou JP, Hatem S., Laurent G., Levade T., Mercaider JJ (1999). L-carnitine prevents doxorubicin-induced apoptosis of cardiac myocytes: Role of inhibition of ceramide generation. FASEB J13: 1501— 1510.
14.
Kapelko VI, Williams CP, Gutstein DE, Morgan JP (1996). Abnormal myocardial calcium handling in the early stage of adriamycin cardiomyopathy. Arch Physiol Biochem104: 185—191.
15.
Boucek Rjj, Miracle A., Anderson M., Engelman R., Atkinson J., Dodd DA ( 1999). Persistant effects of doxorubicin on cardiac gene expression . J Mol Cell Cardiol31: 1435—1446.
16.
Sazuka Y., Tanizawa H., Takino Y. (1989). Effect of adriamycin on DNA, RNA and protein biosyntheses in mouse tissues, in connection with its cardiotoxicity. Jpn J Cancer Res80: 1000—1005.
17.
Arnaiz SL, Llesuy S. (1993). Oxidative stress in mouse heart by antitumoral drugs: A comparative study of doxorubicin and mitoxantrone. Toxicology77: 31—38.
18.
Crescimanno M., Flandina C., Rausa L., Sanguedolce R., D'Alessandro N. (1988). Morphological changes and catalase activity in the hearts of CD 1 mice following acute starvation or single doses of doxorubicin, epirubicin or mitoxantrone . Chemioterapia7: 53—59.
19.
D'Alessandro N., Rausa L., Crescimanno M. (1988). In vivo effects of doxorubicin and isoproterenol on reduced glutathione and H2O2 production in mouse heart. Res Comm Chem PatholPharmacol62: 19—30.
20.
Yin X., Wu H., Chen Y., Kang YJ ( 1998). Induction of antioxidants by adriamycin in mouse heart . Biochem Pharmacol56: 87—93.
21.
Frankel D., Mehindate K., Schipper HM (2000). Role of heme oxygenase-1 in the regulation of manganese superoxide dismutase gene expression in oxidatively-challenged astroglia . J Cell Physiol185: 80—86.
22.
Nakamura T. , Ueda Y., Juan Y., Katsuda S., Takahashi H., Koh E. (2000). Fas-mediated apoptosis in adriamycin-induced cardiomyopathy in rats: In vivo study. Circulation102: 572—578.
23.
Toyoda Y., Okada M., Kashem MA (1998). A canine model of dilated cardiomyopathy induced by repetitive intracoronary doxorubicin administration. J Thor Cardiovasc Surg115: 1367—1373.
24.
Ruwhof C., van der Laarse A. (2000). Mechanical stress-induced cardiac hypertrophy: Mechanisms and signal transduction pathways. Cardiovasc Res47: 23—37.
25.
Pinkus R., Weiner LM, Daniel V. (1995). Role of quinone-mediated generation of hydroxyl radical in the induction of glutathione S-transferase gene expression. Biochemistry34: 81—88.
26.
Jeyaseelan R., Poizat C., Wu HY, Kedes L. (1997). Molecular mechanisms of doxorubicin-induced cardiomyopathy. J Biol Chem272: 5828—5832.
27.
Gewirtz DA (1999). A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and dauorubicin. Biochem Pharmacol57: 727—741.
28.
Ishii T., Itoh K., Takahashi S., Sato H., Yanagawa T., Katoh Y., Bannai S., Yamamoto M. (2000). Transcription factor Nrf2 coordinately regulates a group of oxidative stress-inducible genes in macrophages. J Biol Chem275: 16023—16029.
29.
Dhakshinamoorthy S., Long DJ2nd, Jaiswal AK (2000). Antioxidant regulation of genes encoding enzymes that detoxify xenobiotics and carcinogens. Curr Top Cell Regul36: 201—216.
30.
Parrilli G. , Iaffaioli RV, Martorano M., Cuomo R., Tafuto S., Zampino MG, Budillon G., Bianco AR (1989). Effects of anthracycline therapy on intestinal absorption in patients with advanced breast cancer. Cancer Res49: 3689— 3691.
31.
Sun Z., Wang X., Wallen R., Deng X., Du X., Hallberg E., Andersson R. (1998). The influence of apoptosis on intestinal barrier integrity in rats. Scand J Gastroenterol33: 415—422.
32.
Okubo S., Yasunaga K. (1983). Clinical and experimental studies on DIC found in carcinoma; correlation between anti-cancer drug administration and endotoxemia . Jpn J Cancer Clin29: 803—806.
33.
Janssen-Heininger YMW , Poynter ME, Baeuerle PA (2000). Recent advances towards understanding redox mechanisms in the activation of nuclear factor κβ . Free Radic Biol Med28: 1317—1327.
34.
Cowan DB, Poutias DN, Del Nido PJ, McGowan FXJ (2000). CD14-independent activation of cardiomyocyte signal transduction by bacterial endotoxin. Am J Physiol Heart Circ Physiol279: H619—629.
35.
Chen CC, Wang JK ( 1999). p38 but not p44/42 mitogen-activated protein kinase is required for nitric oxide synthase induction mediated by lipopolysaccharide in RAW 264.7 macrophages. Mol Pharmacol55: 481—488.
36.
Chen G., McCuskey RS, Reichlin S. (2000). Blood interleukin-6 and tumor necrosis factor-alpha elevation after intracerebroventricular injection of Escherichia coli endotoxin in the rat is determined by two opposing factors: Peripheral induction by LPS transferred from brain to blood and inhibition of peripheral response by a brain-mediated mechanism. Neuroimmunomodulation8: 59—69.
37.
Matsumoto T. , Tateda K., Miyazaki S., Furuya N., Ohno A., Ishii Y., Hirakata Y., Yamaguchi K. (1999). Fosfomycin alters lipopolysaccharide-induced inflammatory cytokine production in mice. Antimicrob Agents Chemother43: 697—698.
38.
Mustapha S. , Kirshner A., De Moissac D., Kirshenbaum LA (2000). A direct requirement of nuclear factor-κβ for suppression of apoptosis in ventricular myocytes. Am J Physiol Heart Circ Physiol279: H939—H945.
39.
Pogrebniak HW, Matthews W., Pass HI (1991). Chemotherapy amplifies production of tumor necrosis factor. Surgery110: 231—237.
40.
Eriksson C. , Nobel S., Winblad B., Schultzberg M. (2000). Expression ofinterleukin 1 alpha and beta, and interleukin 1 receptor antagonist mRNA in the rat central nervous system after peripheral administration of lipopolysaccharides. Cytokine12: 423—431.
41.
Stefanelli C., Pignatti C., Tantini B., Stanic I., Bonavita F., Muscari C., Guarnieri C., Clo C., Caldarera CM (1999). Nitric oxide can function as either a killer molecule or an antiapoptotic effector in cardiomyocytes . Biochim Biophys Acta1450: 406—413.
42.
Kibbe MR, Li J., Nie S., Watkins SC, Lizonova A., Kovesdi I., Simmons RL, Billiar TR, Tzeng E. (2000). Inducible nitric oxide synthase (iNOS) expression upregulates p21 and inhibits vascular smooth muscle cell proliferation through p42/44 mitogen-activated protein kinase activation and independent of p53 and cyclic guanosine monophosphate. J Vasc Surg31: 1214—1228.
43.
Weinstein DM , Mihm MJ, Bauer JA (2000). Cardiac peroxynitrite formation and left ventricular dysfunction following doxorubicin treatment in mice. J Pharmacol Exp Ther294: 396—401.
44.
Tabrizi SJ, Schapira AH (1999). Secondary abnormalities of mitochondrial DNA associated with neurodegeneration. Biochem Soc Symp66: 99—110.
45.
Yen HC, Oberley TD, Gairola CG, Szweda LI, St Clair DK (1999). Manganese superoxide dismutase protects mitochondrial complex I against adriamycin-induced cardiomyopathy in transgenic mice. Arch Biochem Biophys362: 59—66.
46.
Nagase I., Yoshida S., Canas X., Irie Y., Kimura K., Yoshida T., Saito M. (1999). Up-regulation of uncoupling protein 3 by thyroid hormone, peroxisome proliferator-activated receptor ligands and 9-cis retinoic acid in L6 myotubes. FEBS Lett461: 319—322.
47.
Valdes Olmos RA, tBHww, ten Hoeve RF, van Tinteren H., Bruning PF, van Vlies B., Hoefnagel CA (1995). Assessment of anthracycline-related myocardial adrenergic derangement by metaiodobenzylguanidine scintigraphy. Eur J Cancer31A: 26—31.
48.
Tretyakova NY, Wishnok JS, Tannenbaum SR (2000). Peroxynitrite-induced secondary oxidative lesions at guanine nucleobases: Chemical stability and recognition by the Fpg DNA repair enzyme. Chem. Res. Toxicol.13: 658—664.
49.
Tretyakova NY , Burney S., Pamir B., Wishnok JS, Dedon PC, Wogan GN, Tannenbaum SR (2000). Peroxynitrite-induced DNA damage in the supF gene: Correlation with the mutational spectrum. Mutat Res447: 287—303.
50.
Codegoni AM, Broggini M., Pitelli MR, Pantarotto M., Torri V., Mangioni C., D'Incalci M. (1997). Expression of genes of potential importance in the response to chemotherapy and DNA repair in patients with ovarian cancer . Gynecol Oncol65: 130—137.
51.
Satyamoorthy K., Perchellet JP (1989). Modulation by adriamycin, daunomycin, verapamil, and trifluoperazine of the biochemical processes linked to mouse skin tumor promotion by 12-O-tetradecanoylphorbol-13-acetate . Cancer Res49: 5364—5370.
52.
Casti A., Guarnieri C., Dall'asta R., Clo C. (1977). Effect of spermine on acetylation of histones in the rabbit heart. J Mol Cell Cardiol9: 63—71.
53.
Cohen SC (1998). A Guide To The Polyamines. Oxford University Press, New York.
54.
Hobbs CA, Gilmour SK (2000). High levels of intracellular polyamines promote histone acetyltransferase activity resulting in chromatin hyper-acetylation . J Cell Biochem77: 345—360.
55.
Flamigni F. , Facchini A., Capanni C., Stefanelli C., Tantini B., Caldarera CM (1999). p44/42 mitogen-activated protein kinase is involved in the expression of ornithine decarboxylase in leukaemia L1210 cells. Biochem J341: 363—369.
56.
Friberg P., Isgaard J., Wahlander A., Wickman A., Adams MA (1998). Inhibited expression of insulin-like growth factor I mRNA and attenuated cardiac hypertrophy in volume overloaded hearts treated with difluoromethylornithine. Growth Horm IGF Res8: 159—165.
57.
Schluter KD , Frischkopf K., Flesch M., Rosenkranz S., Taimor G., Piper HM (2000). Central role for ornithine decarboxylase in beta-adrenoceptor mediated hypertrophy . Cardiovasc Res45: 410—417.
58.
Wang GW, Kang YJ ( 1998). Inhibition of doxorubicin toxicity in cultured neonatal mouse cardiomyocytes with elevated metallothionein levels. J Pharmacol Exp Ther288: 938—944.
59.
Stefanelli C., Stanic I., Zini M., Bonavita F., Flamigni F., Zambonin L., Landi L., Pignatti C., Guarnieri C., Caldarera CM (2000). Polyamines directly induce release of cytochrome c from heart mitochondria . Biochem J347: 875—880.
60.
Kurabayashi M., Dutta S., Jeyaseelan R., Kedes L. (1995). Doxorubicin-induced Id2A gene transcription is targeted at an activating transcription factor/cyclic AMP response element motif through novel mechanisms involving protein kinases distinct from protein kinase C and protein kinase A. Mol Cell Biol15: 6386—6397.
61.
Jeyaseelan R., Poizat C., Baker RK, Abdishoo S., Isterabadi LB, Lyons GE, Kedes L. (1997). A novel cardiac-restricted target for doxorubicin. J Biol Chem272: 22800—22808.
62.
Wang L., Ma W., Markovich R., Lee WL, Wang PH ( 1998). Insulin-like growth-factor I modulates induction of apoptotic signaling in H9c2 cardiac muscle cells. Endocrinology139: 1354—1360.
63.
Kumar D., Kirshenbaum L., Li T., Danelisen I., Singal P. (1999). Apoptosis in isolated adult cardiomyocytes exposed to adriamycin. Ann NY Acad Sci874: 156—168.
64.
Morjani H., Pignon B., Millot JM, Debal V., Lamiable D., Potron G., Etienne JC, Manfait M. (1992). Intranuclear concentration measurements of doxorubicin in living leukocytes from patients treated for a lympho-proliferative disorder . Leuk Res16: 647—653.
65.
Long DJN , Jaiswal AK (2000). Mouse NRH: quinone oxidoreductase (NQO2): Cloning of cDNA and gene- and tissue specific expression. Gene252: 107—117.
66.
Wang YM, Madanat FF, Kimball JC, Gleiser CA, Ali MK, Kaufman MW, van Eys J. (1980). Effect of vitamin E against adriamycin-induced toxicity in rabbits. Cancer Res40: 1022—1027.
67.
Prestera T. , Holtzclaw WD, Zhang Y., Talalay P. (1993). Chemical and molecular regulation of enzymes that detoxify carcinogens. Proc Natl Acad Sci USA90: 2965—2969.
68.
Inamdar NM, Ahn YI, Alam J. ( 1996). The heme-responsive element of the mouse heme oxygenase-1 gene is an extended AP-1 binding site that resembles the recognition sequences MAF and NF-E2 transcription factors. Biochem Biophys Res Commun221: 570—576.
69.
Prestera T. , Talalay P., Alam J., Ahn YI, Lee PJ, Choi AM (1995). Parallel induction of heme oxygenase-1 and chemoprotective phase 2 enzymes by electrophiles and antioxidants: Regulation by upstream antioxidant-responsive elements (ARE) . Mol Med1: 827—837.
70.
Elbirt KK, Bonkovsky HL (1999). Heme oxygenase: Recent advances in understanding its regulation and role. Proc Assoc Am Phys111: 438—447.
71.
Vile GF, Basu-Modak S., Waltner C., Tyrrell RM (1994). Heme oxygenase 1 mediates an adaptive response to oxidative stress in human skin fibroblasts. Proc Natl Acad Sci USA91: 2607—2610.
72.
Tsuji Y., Ayaki H., Whitman SP, Morrow CS, Torti SV, Torti FM (2000). Coordinate transcriptional and translational regulation offerritin in response to oxidative stress. Mol Cell Biol20: 5818—5827.
73.
Dorner A., Schultheiss HP (2000). The myocardial expression of the adenine nucleotide translocator isoforms is specifically altered in dilated cardiomyopathy. Herz25: 176—180.
74.
Van Vleet JF, Ferrans VJ, Badylak SF (1982). Effect of thyroid hormone supplementation on chronic doxorubicin (adriamycin)-induced cardiotoxicity and serum concentrations of T3 and T4 in dogs. Am J Vet Res43: 2173—2182.
75.
Kahl S., Elsasser TH, Blum JW ( 2000). Effect of endotoxin challenge on hepatic 5'-deiodinase activity in cattle. Domest AnimEndocrinol18: 133— 143.
76.
Ito H., Miller SC, Billingham ME, Akimoto H., Torti SV, Wade R., Gahlmann R., Lyons G., Kedes L., Torti FM (1990). Doxorubicin selectively inhibits muscle gene expression in cardiac muscle cells in vivo and in vitro. Proc Natl Acad Sci USA87: 4275—4279.
